VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Nimi VRTXON

Koht No.3637

Turulagi $0.00

Täielikult lahjendatud turukapital $0.00

Turuosa %

Kauplemismaht/turukapital (24H) 19,434,380.43%

Ringlev varu 3.84400459

Maksimaalne varu 0

Koguvaru 3.84400459

Ringluse määr %

Väljaandmise kuupäev --

Hind, millega vara esmakordselt välja anti --

Kõigi aegade kõrgeim 466.35223147502205, 2026-03-26

Madalaim hind 414.92035330237934, 2026-05-05

Avalik plokiahel VRTXON

Tutvustus Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sotsiaalmeedia

• Twitter

• Ametlik veebisait
• Blokeerige Explorer

Vahendite voolu analüüs

etfindex:mc_etfindex_source Lahtiütlus: Andmed on esitanud cmc ja neid ei tohiks käsitleda investeerimisnõuannetena.